Why Is MADRIGAL PHARMACEUTI (MDGL) Stock Down Today?

MDGL stock fell 9.83% to $493.11 in early trading on July 30, 2026, amid a mixed backdrop of analyst activity and recent insider sales. The sharp decline came after the company released its Q2 2026 earnings report, which showed strong revenue growth but also highlighted ongoing losses and a one-time $25 million expense. Analysts have been adjusting their price targets and coverage, with Barclays lowering its target to $962 and H.C. Wainwright reiterating a buy rating.

What Happened

Madrigal Pharmaceuticals reported Q2 2026 results that included a 71% year-over-year increase in Rezdiffra sales and a doubling of its patient base. GAAP earnings per share were -$1.99, which beat estimates by $0.65, while revenue reached $364.3 million, exceeding expectations by $11.13 million. The company also announced new intellectual property protections and late-stage pipeline progress. However, the earnings report included a one-time $25 million expense and continued negative net income, which may have weighed on investor sentiment.

Analysts have responded with mixed signals. Barclays cut its price target to $962, while H.C. Wainwright maintained a buy rating. Wells Fargo initiated coverage with an overweight rating and a $685 price target. Meanwhile, recent insider transactions have raised attention, with four sales totaling $5.2 million reported in the last 90 days, including sales by the CEO and other executives.

What The Data Shows

MDGL has a market cap of $12.4 billion, with a GAAP EPS of -$1.99 for the quarter and a trailing 12-month EPS of -$13.65. Revenue grew 256.8% TTM, but the company remains unprofitable with a net margin of -27.3%. The stock is currently trading within its 52-week range of $286.44 to $615.00. Intraday trading showed no movement from the opening price of $495.00, with zero shares traded so far in the session.

What To Watch

The stock will be closely watched for further analyst activity and investor reaction to the earnings report. No upcoming earnings date is provided, but coverage breadth and insider activity will remain key factors to monitor.